Aarti Industries Ltd Q4 FY2022 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/0dgfxqi31ab37k2aluho8fdq.pdf

Key Takeaways


The Three-Contract Engine: Ramp-Up & Revenue Conversion

Rajendra Gogri: "Significant jump in the next 3 years in EBITDA will happen because by that time our capacity utilization will reach 80-90%."

Nitric Acid: The Bottleneck & The Fix

Rajendra Gogri: "My price may be INR 5-10 higher, but know the multiplier effect for us is much more if the material is not available."

FY23–FY25 Earnings Trajectory

Rajendra Gogri: "At the EBITDA level, we feel whatever the guidance which we have given on FY24, we should be able to reach those level in next year."

New Chemistry Pipeline & CapEx Deployment


Pharma Demerger & Segment Performance


People, Costs & Operating Context

Rajendra Gogri: "One of the key challenges going forward will be how do you manage the talent? So that is why, we like to have some cushion in the talent and also do continuous internal training to upgrade the people."

Guidance & Commitments

CommitmentSpecificsTimeline
FY24 EBITDAReach previously guided FY24 level (1.7–2x)Next year (FY23)
FY23 EBITDA growthHigh single-digit growth (on base including ₹138 crore shortfall fee)FY23
Second contract revenueIncremental revenue of over ₹500 croreBy end-FY23
First contract plant utilisation70–80% utilisation for the cancelled-contract plantBy FY24
Overall capacity utilisationMost capacities at 70–90% utilisationBy FY24
CapEx₹3,000 crore+ investedBy FY24
Nitric acid concentration plantCommercialised, capacity 225–250 tpd, cost ₹150–200 croreBy end-FY24
New API facility (Tarapur)CommercialisedQ1 FY23
Pharma demergerNCLT hearing, then 2–3 months for formalities and listingHearing June 2022
Long-term nitric acid strategyComprehensive strategy clarifiedBy Q1 FY24

Key Metrics

MetricQ4 FY22
Revenue₹2,018 cr, +50% YoY
EBITDA₹339 cr, +30% YoY; +52% YoY normalising for ₹37 cr shortfall fees in Q4 FY21
EBITDA margin16.8%
Profit after tax₹194 cr, +39% YoY
Speciality Chemicals revenue₹1,629 cr, +49% YoY
Speciality Chemicals EBIT₹246 cr, +19% YoY
Pharma revenue₹388 cr, +52% YoY
Pharma EBIT₹67 cr, +30% YoY
FY23 EBITDA growth guidanceHigh single digit YoY, on a base including ₹138 cr shortfall fee in FY22
FY24 EBITDA guidance1.7x to 2x FY21 EBITDA
Nitrochlorobenzene production19,551 MT, vs 19,100 MT in Q4 FY21 and 18,504 MT in Q3 FY22
Nitro-Toluene production5,155 MT, vs 2,935 MT in Q4 FY21 and 3,633 MT in Q3 FY22
Hydrogenated products production3,029 MT, vs 1,935 MT in Q4 FY21 and 2,878 MT in Q3 FY22
CAPEX incurred in Q4₹360 cr; FY22 total CAPEX over ₹1,300 cr
Employee additions in FY22~1,500 personnel onboarded; total workforce roughly 8,000-8,500